HIGHLIGHTS
- who: N Raghavendra babu from the (UNIVERSITY) have published the research work: NEW FTIR METHOD DEVELOPMENT AND VALIDATION FOR QUANTITATIVE ANALYSIS OF FAVIPIRAVIR IN BULK AND PHARMACEUTICAL DOSAGE FORMS, in the Journal: (JOURNAL)
- what: Tcalculated=2.21
SUMMARY
Favipiravir is a pyrazine carboxamide derivative that possesses anti-RNA viral action. Favipiravir is transformed to ribofuranosyl triphosphate by host enzymes and inhibits influenza viral RNA-dependent RNA_polymerase selectively. RNAdependent RNA_polymerase (RdRp) enzymes are required for the transcription and replication of viral genomes and serve as antiviral targets. To inhibiting the replication of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.